Unknown PHASE3 INTERVENTIONAL NCT00053560

To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids

A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids

Sponsor: Genelabs Technologies

Conditions Lupus

Interventions Prasterone (GL701)

Updated 7 times since 2017 Last updated: Dec 26, 2007 Started: Dec 31, 2002 Completion: Aug 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Lupus, this trial is ongoing. The trial is conducted by Genelabs Technologies and has accumulated 7 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE3
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE3

First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genelabs Technologies

Data source: Genelabs Technologies

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Brooklyn, United States , Chicago, United States , Duncansville, United States , Fort Lauderdale, United States , Galveston, United States , Los Angeles, United States , Manhasset, United States , Mexico City, Mexico , Nashville, United States and 16 more locations